Patient characteristics
| Patients . | Binet stage . | Treatment status . | IgVH mutational status* . | ZAP-70 expression† . | CD38 expression‡ . |
|---|---|---|---|---|---|
| B-CLL 1 | A | Untreated | Mutated | 70.3 | 0.6 |
| B-CLL 2 | A | Untreated | Mutated | 10.1 | 2.6 |
| B-CLL 3 | B | Untreated | Unmutated | 41.8 | 1.7 |
| B-CLL 4 | A | Untreated | Mutated | 23.2 | 0.2 |
| B-CLL 5 | A | Untreated | Mutated | 92.0 | 1.5 |
| B-CLL 6 | C | Treated§ | Unmutated | 72.0 | 73.2 |
| B-CLL 7 | B | Treated§ | Unmutated | 4.6 | 81.0 |
| B-CLL 8 | B | Untreated | Unmutated | 86.1 | 57.2 |
| B-CLL 9 | B | Untreated | Unmutated | 32.0 | 0.5 |
| B-CLL 10 | B | Treated§ | Mutated | 95.4 | 0.2 |
| B-CLL 11 | B | Untreated | Unmutated | 73.2 | 64.4 |
| B-CLL 12 | B | Untreated | Unmutated | 92.8 | 0.4 |
| B-CLL 13 | B | Treated§ | Mutated | 61.2 | 5.0 |
| B-CLL 14 | C | Treated§ | ND | 71.5 | 96.0 |
| B-CLL 15 | B | Untreated | Mutated | 60.9 | 1.6 |
| B-CLL 16 | B | Untreated | Unmutated | 51.6 | 10.1 |
| B-CLL 17 | B | Untreated | Mutated | ND | ND |
| B-CLL 18 | A | Untreated | Unmutated | 67.4 | 13.0 |
| B-CLL 19 | B | Untreated | Unmutated | 97.6 | 1.6 |
| B-CLL 20 | B | Untreated | Unmutated | 30.5 | 3.6 |
| B-CLL 21 | B | Untreated | Unmutated | 29.1 | 1.7 |
| B-CLL 22 | C | Treated§ | Mutated | ND | ND |
| B-CLL 23 | C | Treated§ | Unmutated | ND | 15.8 |
| B-CLL 24 | B | Untreated | Unmutated | 44.5 | 2.9 |
| B-CLL 25 | B | Untreated | Unmutated | 60.1 | 10.6 |
| Patients . | Binet stage . | Treatment status . | IgVH mutational status* . | ZAP-70 expression† . | CD38 expression‡ . |
|---|---|---|---|---|---|
| B-CLL 1 | A | Untreated | Mutated | 70.3 | 0.6 |
| B-CLL 2 | A | Untreated | Mutated | 10.1 | 2.6 |
| B-CLL 3 | B | Untreated | Unmutated | 41.8 | 1.7 |
| B-CLL 4 | A | Untreated | Mutated | 23.2 | 0.2 |
| B-CLL 5 | A | Untreated | Mutated | 92.0 | 1.5 |
| B-CLL 6 | C | Treated§ | Unmutated | 72.0 | 73.2 |
| B-CLL 7 | B | Treated§ | Unmutated | 4.6 | 81.0 |
| B-CLL 8 | B | Untreated | Unmutated | 86.1 | 57.2 |
| B-CLL 9 | B | Untreated | Unmutated | 32.0 | 0.5 |
| B-CLL 10 | B | Treated§ | Mutated | 95.4 | 0.2 |
| B-CLL 11 | B | Untreated | Unmutated | 73.2 | 64.4 |
| B-CLL 12 | B | Untreated | Unmutated | 92.8 | 0.4 |
| B-CLL 13 | B | Treated§ | Mutated | 61.2 | 5.0 |
| B-CLL 14 | C | Treated§ | ND | 71.5 | 96.0 |
| B-CLL 15 | B | Untreated | Mutated | 60.9 | 1.6 |
| B-CLL 16 | B | Untreated | Unmutated | 51.6 | 10.1 |
| B-CLL 17 | B | Untreated | Mutated | ND | ND |
| B-CLL 18 | A | Untreated | Unmutated | 67.4 | 13.0 |
| B-CLL 19 | B | Untreated | Unmutated | 97.6 | 1.6 |
| B-CLL 20 | B | Untreated | Unmutated | 30.5 | 3.6 |
| B-CLL 21 | B | Untreated | Unmutated | 29.1 | 1.7 |
| B-CLL 22 | C | Treated§ | Mutated | ND | ND |
| B-CLL 23 | C | Treated§ | Unmutated | ND | 15.8 |
| B-CLL 24 | B | Untreated | Unmutated | 44.5 | 2.9 |
| B-CLL 25 | B | Untreated | Unmutated | 60.1 | 10.6 |
ND indicates not determined.
Mutated was defined as having a frequency of mutations greater than 2% from germline VH.
Values represent percentage of B-CLL cells expressing intracellular ZAP-70.
Values represent percentage of B-CLL cells expressing surface CD38.
Patients had not received treatment for at least 3 months prior to the study.